Ask AI
Targeting DLL3 for EP NECs

CME

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 30, 2025

Expiration: March 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is commonly associated with poorly differentiated NECs but not well-differentiated neuroendocrine tumors (NETs)?

2.

Which clinical strategy targeting DLL3 is currently approved for small-cell lung cancer (SCLC) and being tested for EP-NEC?

3.

Which of the following was reported from the ongoing phase I trial of obrixtamig in SCLC, EP-NEC, and large-cell (LC) NEC?

4.

With which patients would you discuss the potential of participation in the phase I DAREON-5 trial of obrixtamig?